Should Pharma Firms Cover CDx Costs For Precision Cancer Drugs?
Executive Summary
Significant financial reward awaits drugmakers that invest more in companion diagnostics during the development and marketing of precision cancer drugs, says Peter Keeling, CEO of Diaceutics – but Novartis warns that relying on pharma firms to fund these tests is unsustainable.
You may also be interested in...
Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA
Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.
Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?
A report comparing the health technology assessment methods used in nine European countries, Australia and Canada found that England has the most favorable reimbursement landscape for gene therapies – but outlined several areas for improvement across the board.